Lurbinectedin in small cell lung cancer: real-world experience of a multicentre national early access programme

Marliese Alexander^{1

2}, Jennifer Rogers¹, Sagun Parakh^{3

4}, Paul Mitchell^{3

5}, Timothy D Clay^{6

7

8}, Steven Kao^{9

10}, Brett G M Hughes^{11

12}, Malinda Itchins^{13

14}, Benjamin Y Kong¹³, Nick Pavlakis^{13

14}, Benjamin J Solomon^{1

2}, Thomas John^{1

2}

Affiliations

¹ Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
² Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
³ Austin Hospital, Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.
⁴ School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia.
⁵ Division of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia.
⁶ Saint John of God Subiaco Hospital, Perth, Western Australia, Australia.
⁷ Icon Cancer Care Midland, Perth, Western Australia, Australia.
⁸ School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia.
⁹ Chris O'Brien Lifehouse, Sydney, New South Wales, Australia.
¹⁰ Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
¹¹ The Prince Charles Hospital, Brisbane, Queensland, Australia.
¹² Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
¹³ Royal North Shore Hospital, Sydney, New South Wales, Australia.
¹⁴ Northern Clinical School, The University of Sydney, Sydney, New South Wales, Australia.

PMID: 38369719
DOI: 10.1111/imj.16348

Multicenter Study

Lurbinectedin in small cell lung cancer: real-world experience of a multicentre national early access programme

Marliese Alexander et al. Intern Med J. 2024 Jul.

. 2024 Jul;54(7):1087-1096.

doi: 10.1111/imj.16348. Epub 2024 Feb 18.

Authors

Affiliations

¹ Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
² Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
³ Austin Hospital, Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.
⁴ School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia.
⁵ Division of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia.
⁶ Saint John of God Subiaco Hospital, Perth, Western Australia, Australia.
⁷ Icon Cancer Care Midland, Perth, Western Australia, Australia.
⁸ School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia.
⁹ Chris O'Brien Lifehouse, Sydney, New South Wales, Australia.
¹⁰ Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
¹¹ The Prince Charles Hospital, Brisbane, Queensland, Australia.
¹² Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
¹³ Royal North Shore Hospital, Sydney, New South Wales, Australia.
¹⁴ Northern Clinical School, The University of Sydney, Sydney, New South Wales, Australia.

PMID: 38369719
DOI: 10.1111/imj.16348

Abstract

Background and aims: Lurbinectedin is a novel oncogenic transcription inhibitor active in several cancers, including small cell lung cancer (SCLC). We aimed to describe the first Australian experience of the clinical efficacy and tolerability of lurbinectedin for the treatment of SCLC after progression on platinum-containing therapy.

Methods: Multicentre real-world study of individuals with SCLC initiating lurbinectedin monotherapy (3.2 mg/m² three-weekly) on an early access programme between May 2020 and December 2021. Key outcomes were clinical utilisation, efficacy and tolerability. Progression-free survival (PFS) and overall survival (OS) were calculated using the Kaplan-Meier method. Outcome data were collected within the AUstralian Registry and biObank of thoRacic cAncers (AURORA).

Results: Data were analysed for 46 individuals across seven sites. Lurbinectedin was given as second- (83%, 38/46) or subsequent- (17%, 8/46) line therapy, mostly with prior chemoimmunotherapy (87%, 40/46). We report dose modifications (17%, 8/46), interruptions/delays (24%, 11/46), high-grade toxicities (28%, 13/46) and hospitalisations (54%, 25/46) during active treatment. The overall response rate was 33% and the disease control rate was 50%. Six-month OS was 44% (95% confidence interval (CI): 29.0-57.1). Twelve-month OS was 15% (95% CI: 6.5-26.8). From lurbinectedin first dose, the median PFS was 2.5 months (95% CI: 1.8-2.9) and OS was 4.5 months (95% CI: 3.5-7.2). From SCLC diagnosis, the median OS was 12.9 months (95% CI: 11.0-17.2). Individuals with a longer chemotherapy-free interval prior to lurbinectedin had longer PFS and OS.

Conclusion: This real-world national experience of lurbinectedin post-platinum chemotherapy and immunotherapy for individuals with SCLC was similar to that reported in clinical trials.

Keywords: lurbinectedin; real‐world data; real‐world evidence; small cell lung cancer; survival outcomes.

PubMed Disclaimer

References

1. Howlader N, Noone AM, Krapcho M. SEER Cancer Statistics Review, 1975‐2018, Based on November 2020 SEER data submission, posted to the SEER web site, April 2021.
1. Sabesan S, Zalcberg J, Underhill C, Zielinski R, Burbury K, Ansari Z et al. Implementation of the Australasian Teletrial Model: lessons from practice. Asia Pac J Clin Oncol 2019; 15: 3–14.
1. Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D'Amico TA et al. Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2021; 19: 1441–1464.
1. O'Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cuceviá B, Juhasz G et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small‐cell lung cancer. J Clin Oncol 2006; 24: 5441–5447.
1. Chen L, Antras L, Duh MS, Neary M, O'Brien ME. Symptom assessment in relapsed small cell lung cancer: cross‐validation of the patient symptom assessment in lung cancer instrument. J Thorac Oncol 2008; 3: 1137–1145.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

Grants and funding

Specialised Therapeutics

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Lurbinectedin in small cell lung cancer: real-world experience of a multicentre national early access programme

Affiliations

Lurbinectedin in small cell lung cancer: real-world experience of a multicentre national early access programme

Authors

Affiliations

Abstract

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical